142 related articles for article (PubMed ID: 7693639)
1. Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A.
Keicho N; Kudoh S; Yotsumoto H; Akagawa KS
J Antibiot (Tokyo); 1993 Sep; 46(9):1406-13. PubMed ID: 7693639
[TBL] [Abstract][Full Text] [Related]
2. Differential effect of rapamycin and cyclosporin A in proliferation in a murine T cell line expressing either intermediate or high affinity receptor for IL-2.
Rebollo A; Mérida I; Gómez J; Pitton C; Silva A; Martínez C; García A
Cytokine; 1995 Apr; 7(3):277-86. PubMed ID: 7543780
[TBL] [Abstract][Full Text] [Related]
3. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation.
Sawada S; Suzuki G; Kawase Y; Takaku F
J Immunol; 1987 Sep; 139(6):1797-803. PubMed ID: 2442255
[TBL] [Abstract][Full Text] [Related]
4. 15-Deoxyspergualin inhibits interleukin 6 production in in vitro stimulated human lymphocytes.
Borg AJ; Kumagai-Braesch M; Möller E
Transpl Immunol; 1996 Jun; 4(2):133-43. PubMed ID: 8843590
[TBL] [Abstract][Full Text] [Related]
5. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin.
Dumont FJ; Staruch MJ; Koprak SL; Melino MR; Sigal NH
J Immunol; 1990 Jan; 144(1):251-8. PubMed ID: 1688572
[TBL] [Abstract][Full Text] [Related]
6. Human T cell responses to human and porcine endothelial cells are highly sensitive to cyclosporin A and FK506 in vitro.
Batten P; McCormack AM; Page CS; Yacoub MH; Rose ML
Transplantation; 1999 Nov; 68(10):1552-60. PubMed ID: 10589954
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro.
Morikawa K; Oseko F; Morikawa S; Sawada M
Antimicrob Agents Chemother; 1993 Dec; 37(12):2684-7. PubMed ID: 7509146
[TBL] [Abstract][Full Text] [Related]
8. Suppression of adult T cell leukemia-derived factor/human thioredoxin induction by FK506 and cyclosporin A: a new mechanism of immune modulation via redox control.
Furuke K; Nakamura H; Hori T; Iwata S; Maekawa N; Inamoto T; Yamaoka Y; Yodoi J
Int Immunol; 1995 Jun; 7(6):985-93. PubMed ID: 7577807
[TBL] [Abstract][Full Text] [Related]
9. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells.
Dumont FJ; Melino MR; Staruch MJ; Koprak SL; Fischer PA; Sigal NH
J Immunol; 1990 Feb; 144(4):1418-24. PubMed ID: 1689353
[TBL] [Abstract][Full Text] [Related]
10. Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis.
Koenen HJ; Michielsen EC; Verstappen J; Fasse E; Joosten I
Transplantation; 2003 May; 75(9):1581-90. PubMed ID: 12792519
[TBL] [Abstract][Full Text] [Related]
11. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation.
Hess DA; Bird IA; Almawi WY; Rieder MJ
J Pharmacol Exp Ther; 1997 Apr; 281(1):540-8. PubMed ID: 9103542
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists.
Hatfield SM; Mynderse JS; Roehm NW
J Pharmacol Exp Ther; 1992 Jun; 261(3):970-6. PubMed ID: 1376361
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 receptor (CD25) upregulation on human T-lymphocytes: sensitivity to immunosuppressants is defined by the mode of T-lymphocyte activation.
Ryffel B; Willcocks JL; Brooks N; Woerly G
Immunopharmacology; 1995 Sep; 30(3):199-207. PubMed ID: 8557519
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of motilin agonism by macrolide immunosuppressive drugs.
Van Vlem B; Schoonjans R; Vanholder R; De Vos M; Depoortere I; Peeters TL; Lefebvre R
Nephrol Dial Transplant; 2002 Jun; 17(6):973-7. PubMed ID: 12032184
[TBL] [Abstract][Full Text] [Related]
15. Suppression of B cell activation by cyclosporin A, FK506 and rapamycin.
Wicker LS; Boltz RC; Matt V; Nichols EA; Peterson LB; Sigal NH
Eur J Immunol; 1990 Oct; 20(10):2277-83. PubMed ID: 1700753
[TBL] [Abstract][Full Text] [Related]
16. FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells.
Sakuma S; Kato Y; Nishigaki F; Sasakawa T; Magari K; Miyata S; Ohkubo Y; Goto T
Br J Pharmacol; 2000 Aug; 130(7):1655-63. PubMed ID: 10928971
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of lymphoproliferative responses by SK&F 105685, a novel anti-arthritic agent.
Kaplan JM; Badger AM; Ruggieri EV; Olivera DL; Newman-Tarr T; Bugelski PJ
J Clin Lab Immunol; 1991 Dec; 36(4):49-58. PubMed ID: 1668843
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of whole-blood T lymphocytes in individual patients to tacrolimus (FK 506): impact of interleukin-2 mRNA expression as surrogate measure of immunosuppressive effect.
Härtel C; Schumacher N; Fricke L; Ebel B; Kirchner H; Müller-Steinhardt M
Clin Chem; 2004 Jan; 50(1):141-51. PubMed ID: 14709642
[TBL] [Abstract][Full Text] [Related]
19. Energy levels in resting and mitogen-stimulated human lymphocytes during treatment with FK506 or cyclosporin A in vitro.
Karlsson H; DePierre JW; Nässberger L
Biochim Biophys Acta; 1997 Apr; 1319(2-3):301-10. PubMed ID: 9131051
[TBL] [Abstract][Full Text] [Related]
20. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level.
Andersson J; Nagy S; Groth CG; Andersson U
Immunology; 1992 Jan; 75(1):136-42. PubMed ID: 1371491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
